Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
In yet another setback to the Merck and Daiichi Sankyo partnership, the companies said they have pulled their FDA accelerated approval application for an antibody-drug conjugate (ADC) in certain small cell lung cancer (SCLC) patients. ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.